High Heregulin mRNA, HER3 Linked to Poor Survival in Oropharyngeal Carcinoma
the Cancer Therapy Advisor take:
Independent associations between high heregulin messenger RNA (mRNA) and high human epidermal growth factor receptor 3 (HER3) protein levels and poor overall survival (OS) were discovered in patients with oropharyngeal squamous cell carcinoma (OPSCC), according to an article published online in the journal Cancer.
The investigators examined 96 primary tumor specimens from patients with OPSCC and analyzed for heregulin mRNA, HER3, and human epidermal growth factor receptor 2 (HER2), using in situ hybridization and immunohistochemistry, respectively.
Results showed heregulin mRNA levels greater than the median value were significantly associated with poor OS (HR, 8.48; 95% CI: 2.17, 33.17; P=0.002) but not disease-free survival (HR, 1.52; 95% CI: 0.64, 3.65; P=0.341) in patients with OPSCC.
Furthermore, a negative correlation was determined between heregulin mRNA and OS in patients with p16-positive (P=0.049) and p16-negative (P=0.091) OPSCC.
Similarly, HER3 levels greater than the median were also associated with poor OS (HR, 4.68; 95% CI: 1.47, 14.90; P=0.009) in patients with OPSCC.
An independent correlation was identified for epidermal growth factor receptor (HER) levels and disease-free survival (P=0.025), while HER was also inversely related to p16 status (P=0.012).
Using The Cancer Genome Atlas database, it was determined that head and neck squamous cell carcinoma exhibited higher levels of heregulin compared to other solid tumor types.
Associations between heregulin mRNA and HER3 protein levels and overall survival discovered in oropharyngeal squamous cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models